Viatris Archives | Market Krystal https://www.marketkrystal.com/chemical-news/company/viatris/ Voice of Chemical Industry Leaders Thu, 08 Oct 2026 11:45:00 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.7 148046184 Viatris to Acquire Pacira BioSciences for $1.65 Billion in Cash https://www.marketkrystal.com/chemical-news/viatris-to-acquire-pacira-biosciences-for-1-65-billion-in-cash/ Thu, 08 Oct 2026 11:45:00 +0000 https://www.marketkrystal.com/chemical-news/viatris-to-acquire-pacira-biosciences-for-1-65-billion-in-cash/ Viatris has agreed to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, via a tender offer followed by…

The post Viatris to Acquire Pacira BioSciences for $1.65 Billion in Cash appeared first on Market Krystal.

]]> Viatris has agreed to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, via a tender offer followed by a second-step merger. Pacira's EXPAREL (bupivacaine liposome injectable suspension) and ZILRETTA (triamcinolone acetonide extended-release injectable suspension) generated approximately $746 million in total revenue and $177 million in adjusted EBITDA in the twelve months ended June 30, 2026. The deal is expected to close by the end of 2026 and be immediately accretive to Viatris' financial guidance metrics.

Why it matters

Viatris will fund the transaction mainly from excess cash with the remainder from short-term borrowings, adding high-margin, patent-protected non-opioid pain products to its innovative medicines portfolio and its meloxicam opportunity.

Key facts

Companies Viatris Inc., Pacira BioSciences, Inc.
Chemicals bupivacaine liposome, triamcinolone acetonide, meloxicam
Investment $1.65 billion aggregate equity value ($36.50 per share in cash)
Timing 2026-10-08, 2026-06-30 (twelve months ended, Pacira financials), by end of 2026 (expected closing), 2026-11-05 (Viatris third-quarter 2026 results)
Partners Pacira BioSciences, Inc., Viatris Inc.
End uses post-surgical pain management, osteoarthritis knee pain, non-opioid pain therapies

Market context

Bupivacaine liposome and triamcinolone acetonide extended-release formulations are long-acting local anesthetic and corticosteroid products used to manage pain without relying on opioids, mainly after surgery and for osteoarthritis knee pain. Demand is driven by hospitals, ambulatory surgery centers, orthopedic practices and pain clinics that want to reduce opioid use and shorten recovery times. Products of this type rely on proprietary drug delivery technology, so patent protection and manufacturing know-how carry significant value. Acquisitions of specialty pain assets like these can tighten competition in the non-opioid segment, shift contracting and pricing dynamics among hospital buyers, and push generic and branded pharmaceutical makers to expand their own pain portfolios. For chemical and API suppliers, such deals matter mainly through changes in sourcing relationships and the manufacturing footprint of the combined company, rather than through immediate shifts in bulk chemical supply or commodity prices.

Source: official release on newsroom.viatris.com. Summary and context written by Market Krystal.

The post Viatris to Acquire Pacira BioSciences for $1.65 Billion in Cash appeared first on Market Krystal.

]]> 2632